United Therapeutics (NASDAQ:UTHR), a company whose shares are moving quickly, is trading 1.6% higher to $62.01. The Dow is trading fractionally lower to 14,492 and the S&P is currently down 0.3% to 1,555.
In the past 52 weeks, United Therapeutics share prices have been bracketed by a low of $36.55 and a high of $70.74 and are now at $62.01, 70% above that low price. The 200-day and 50-day moving averages have moved 0.90% higher and 1.65% higher over the past week, respectively.
United Therapeutics (NASDAQ:UTHR) is currently priced 8.5% above its average consensus analyst price target of $56.73. The stock should discover initial support at its 50-day moving average (MA) of $55.84 and subsequent support at its 200-day MA of $53.10.
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.